Metagenomi uses metagenomics and machine learning to discover novel genome editing systems for therapeutics development.
Metagenomi has raised $100.0M in total funding. The most recent round was Series B. The last funding was announced in January 2023.
Metagenomi's investors include RA Capital Management, HOF Capital, Catalio Capital Management, Moderna, Sozo Ventures.
Metagenomi is headquartered in Emeryville, United States.
Metagenomi uses metagenomics and machine learning to discover novel genome editing systems for therapeutics development.
Metagenomi is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Metagenomi — Funding & Investors." VCBacked, January 5, 2023, https://www.vcbacked.co/company/metagenomi. Accessed September 30, 2026.
VCBacked. (2023). Metagenomi — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/metagenomi
{{cite web |title=Metagenomi — Funding & Investors |url=https://www.vcbacked.co/company/metagenomi |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated